BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 19474116)

  • 21. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic performance of 18F-2-fluoro-2-deoxy-D-glucose PET/computerized tomography in identifying bone marrow infiltration in new patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Kandeel AA; Hussein M; Zidan L; Younis J; Edesa W; Alsayed Y
    Nucl Med Commun; 2020 Mar; 41(3):269-279. PubMed ID: 31895758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usefulness of (18)F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin's Lymphoma.
    Lee Y; Hwang KH; Hong J; Park J; Lee JH; Ahn JY; Kim JH; Lee H; Kim SG; Shin JY
    Nucl Med Mol Imaging; 2012 Dec; 46(4):269-77. PubMed ID: 24900074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin's lymphoma?
    Tsujikawa T; Otsuka H; Morita N; Saegusa H; Kobayashi M; Okazawa H; Nishitani H
    Ann Nucl Med; 2008 Jan; 22(1):23-30. PubMed ID: 18250984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
    Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
    Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring the role of FDG-PET in the assessment of bone marrow involvement in lymphoma patients as interpreted by qualitative and semiquantitative disease metabolic activity parameter.
    Kand PG; Tiwari BP; Basu S; Asopa RV; Nayak UN
    Indian J Cancer; 2010; 47(4):380-4. PubMed ID: 21131749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of bone marrow biopsy in staging of patients with classical Hodgkin's lymphoma undergoing positron emission tomography/computed tomography.
    Puccini B; Nassi L; Minoia C; Volpetti S; Ciancia R; Riccomagno PC; Di Rocco A; Mulè A; Toldo C; Sassone MC; Guariglia R; Filì C; Finolezzi E; Falorio S; Zanon S; Furlan A; Doa G; Zaja F;
    Ann Hematol; 2017 Jul; 96(7):1147-1153. PubMed ID: 28451805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study.
    Pelosi E; Penna D; Douroukas A; Bellò M; Amati A; Arena V; Passera R; Bisi G
    Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):469-75. PubMed ID: 21150862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
    Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma.
    Papajík T; Mysliveček M; Sedová Z; Buriánková E; Procházka V; Koranda P; Raida L; Kubová Z; Palová M; Kučerová L; Flodr P; Jarkovský J; Dušek L; Indrák K
    Eur J Haematol; 2011 Jan; 86(1):32-7. PubMed ID: 20874822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions.
    Cerci JJ; Trindade E; Buccheri V; Fanti S; Coutinho AM; Zanoni L; Linardi CC; Celli M; Delbeke D; Pracchia LF; Pitela FA; Soares J; Zinzani PL; Meneghetti JC
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):314-20. PubMed ID: 21816369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Value of 18F-FDG PET/CT in Detecting Bone Marrow Involvement in Childhood Cancers.
    Yağci-Küpeli B; Koçyiğit-Deveci E; Adamhasan F; Küpeli S
    J Pediatr Hematol Oncol; 2019 Aug; 41(6):438-441. PubMed ID: 31033787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value of
    Alobthani G; Romanov V; Isohashi K; Matsunaga K; Watabe T; Kato H; Tatsumi M; Shimosegawa E; Hatazawa J
    Hell J Nucl Med; 2018; 21(1):7-14. PubMed ID: 29550841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.
    El-Galaly TC; d'Amore F; Mylam KJ; de Nully Brown P; Bøgsted M; Bukh A; Specht L; Loft A; Iyer V; Hjorthaug K; Nielsen AL; Christiansen I; Madsen C; Johnsen HE; Hutchings M
    J Clin Oncol; 2012 Dec; 30(36):4508-14. PubMed ID: 23150698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct comparison of visual and quantitative bone marrow FDG-PET/CT findings with bone marrow biopsy results in diffuse large B-cell lymphoma: does bone marrow FDG-PET/CT live up to its promise?
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Acta Radiol; 2015 Oct; 56(10):1230-5. PubMed ID: 25387723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Routine bone marrow biopsy is not necessary in the staging of patients with classical Hodgkin lymphoma in the 18F-fluoro-2-deoxyglucose positron emission tomography era.
    Richardson SE; Sudak J; Warbey V; Ramsay A; McNamara CJ
    Leuk Lymphoma; 2012 Mar; 53(3):381-5. PubMed ID: 21877882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of ¹⁸F FDG-PET/CT in the detection of bone marrow disease in Hodgkin's lymphoma.
    Muzahir S; Mian M; Munir I; Nawaz MK; Faruqui ZS; Mufti KA; Bashir H; Uddin N; Siddiqui N; Maaz AU; Mahmood MT
    Br J Radiol; 2012 Aug; 85(1016):e490-6. PubMed ID: 22215887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone involvement in patients with lymphoma: the role of FDG-PET/CT.
    Schaefer NG; Strobel K; Taverna C; Hany TF
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):60-7. PubMed ID: 17021808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of bone marrow biopsy and fluorodeoxyglucose-positron emission tomography for the assessment of bone marrow infiltration in children with Hodgkin's lymphoma.
    Arslantaş E; Ayçiçek A; Akıcı F; Özkara S; Yılmaz B; Özdemir N; Bayram C
    Nuklearmedizin; 2023 Feb; 62(1):20-26. PubMed ID: 36746148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?
    Mittal BR; Manohar K; Malhotra P; Das R; Kashyap R; Bhattacharya A; Varma N; Varma S
    Leuk Lymphoma; 2011 Nov; 52(11):2111-6. PubMed ID: 21745169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.